Virax Biolabs Group (Virax Biolabs Group) Common Stock : $0.00 Mil (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

Virax Biolabs Group Common Stock Definition

Virax Biolabs Group's quarterly common stock increased from Sep. 2022 ($0.00 Mil) to Mar. 2023 ($0.00 Mil) but then stayed the same from Mar. 2023 ($0.00 Mil) to Sep. 2023 ($0.00 Mil).

Virax Biolabs Group's annual common stock increased from Mar. 2021 ($0.00 Mil) to Mar. 2022 ($0.00 Mil) and increased from Mar. 2022 ($0.00 Mil) to Mar. 2023 ($0.00 Mil).

Virax Biolabs Group Common Stock Historical Data

The historical data trend for Virax Biolabs Group's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Common Stock Chart

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Common Stock

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Common Stock	Get a 7-Day Free Trial			-	-	-	-	-

Virax Biolabs Group Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Virax Biolabs Group (Virax Biolabs Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 North Audley Street, London, GBR, W1K 6LX

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.